Amani Ouedrani
YOU?
Author Swipe
View article: Baseline Cognitive and Neurological Status Does Not Modify the Occurrence of <scp>ICANS</scp> in <scp>CAR</scp> T‐Cell Therapy for Aggressive B‐Cell Lymphoma
Baseline Cognitive and Neurological Status Does Not Modify the Occurrence of <span>ICANS</span> in <span>CAR</span> T‐Cell Therapy for Aggressive B‐Cell Lymphoma Open
Background Immune effector cell‐associated neurotoxicity syndrome (ICANS) is a common, serious complication of CAR T‐cell therapy for blood cancers. This study evaluates the impact of baseline cognitive status and pre‐existing neurological…
View article: On behalf of the SFGM‐TC: Real‐life use of third‐party virus‐specific T‐cell transfer in immunocompromised transplanted patients
On behalf of the SFGM‐TC: Real‐life use of third‐party virus‐specific T‐cell transfer in immunocompromised transplanted patients Open
International audience
View article: Case Report: Immune Checkpoint Blockade Plus Interferon-Γ Add-On Antifungal Therapy in the Treatment of Refractory Covid-Associated Pulmonary Aspergillosis and Cerebral Mucormycosis
Case Report: Immune Checkpoint Blockade Plus Interferon-Γ Add-On Antifungal Therapy in the Treatment of Refractory Covid-Associated Pulmonary Aspergillosis and Cerebral Mucormycosis Open
Invasive fungal diseases (IFD) still cause substantial morbidity and mortality, and new therapeutic approaches are urgently needed. Recent data suggest a benefit of checkpoint inhibitors (ICI). We report the case of a diabetic patient with…
View article: Effective Anti–SARS-CoV-2 Immune Response in Patients With Clonal Mast Cell Disorders
Effective Anti–SARS-CoV-2 Immune Response in Patients With Clonal Mast Cell Disorders Open
View article: Anti-CD38 therapy impairs SARS-CoV-2 vaccine response against alpha and delta variants in patients with multiple myeloma
Anti-CD38 therapy impairs SARS-CoV-2 vaccine response against alpha and delta variants in patients with multiple myeloma Open
International audience
View article: Absence of severe COVID-19 in patients with clonal mast cells activation disorders: effective anti-SARS-CoV-2 immune response
Absence of severe COVID-19 in patients with clonal mast cells activation disorders: effective anti-SARS-CoV-2 immune response Open
Mast cells are key actors of innate immunity and Th2 adaptive immune response which counterbalance Th1 response, critical for anti-viral immunity. Clonal Mast Cells Activation Disorders (cMCADs) such as mastocytosis and clonal mast cells a…
View article: Anti-CD38 therapy impairs SARS-CoV-2 vaccine response in multiple myeloma patients
Anti-CD38 therapy impairs SARS-CoV-2 vaccine response in multiple myeloma patients Open
Multiple myeloma (MM) patients are at risk of fatal outcome after SARS-CoV-2 infection. Preliminary data suggest that MM patients have an impaired response to vaccination. This prospective study analyzed the humoral and cellular immune res…
View article: Pseudo-engelures de l’enfant et SARS-CoV-2 : quel lien ?
Pseudo-engelures de l’enfant et SARS-CoV-2 : quel lien ? Open
View article: Severe COVID-19 in Patients with B Cell Alymphocytosis and Response to Convalescent Plasma Therapy
Severe COVID-19 in Patients with B Cell Alymphocytosis and Response to Convalescent Plasma Therapy Open
View article: Immunological and virological profile of children with chilblain‐like lesions and SARS‐CoV‐2
Immunological and virological profile of children with chilblain‐like lesions and SARS‐CoV‐2 Open
International audience
View article: Convalescent plasma therapy for B-cell–depleted patients with protracted COVID-19
Convalescent plasma therapy for B-cell–depleted patients with protracted COVID-19 Open
Anti-CD20 monoclonal antibodies are widely used for the treatment of hematological malignancies or autoimmune disease but may be responsible for a secondary humoral deficiency. In the context of COVID-19 infection, this may prevent the eli…
View article: Safety of CD34+ Hematopoietic Stem Cells and CD4+ T Lymphocytes Transduced with LVsh5/C46 in HIV-1 Infected Patients with High-Risk Lymphoma
Safety of CD34+ Hematopoietic Stem Cells and CD4+ T Lymphocytes Transduced with LVsh5/C46 in HIV-1 Infected Patients with High-Risk Lymphoma Open
View article: 225. Preserving CD4+ T-Cells Phenotype and Function Upon Ex Vivo Lentiviral Transduction
225. Preserving CD4+ T-Cells Phenotype and Function Upon Ex Vivo Lentiviral Transduction Open
Ex vivo gene modification of T-cell is an appealing strategy for the treatment of both immunodeficiencies and neoplasia. Cell activation remains an essential prerequisite to genetic modification by lentiviral transduction. However, most cu…